TY - JOUR
T1 - Subretinal fluid in uveitic macular edema
T2 - Effect on vision and response to therapy
AU - Lehpamer, Brian
AU - Moshier, Erin
AU - Goldberg, Naomi
AU - Ackert, Jessica
AU - Godbold, James
AU - Jabs, Douglas A.
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for disclosure of potential conflicts of interest. Douglas A. Jabs discloses the following consultant relationships: Abbott Laboratories, Applied Genetic Technologies Corporation (AGTC), Alcon Laboratories, Allergan Pharmaceutical Corporation, Corcept Therapeutics, GenenTech Inc, Genzyme Corporation, GlaxoSmithKline, Novartis Pharmaceutical Corp, and Roche Pharmaceuticals. Publication of this article was supported in part by an unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York, and in part by award number UL1RR029887 from the National Center for Research Resources . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Involved in design of the study (D.A.J.); conduct of the study (B.L., N.G., J.A., D.A.J.); collection of the data (B.L.); management of the data (B.L.); analysis of the data (B.L., E.M., J.G., D.A.J.); interpretation of the data (B.L., E.M., J.G., D.A.J.); preparation of the manuscript (B.L., N.G., J.A., J.G.); review of the manuscript (J.G., N.G., J.A., D.A.J.); and approval of the manuscript (J.G., D.A.J.). Prospective approval for this retrospective review of data was granted by the Mount Sinai School of Medicine Institutional Review Board, the Program for the Protection of Human Subjects. The Mount Sinai IRB approved a Waiver of Authorization for use and disclosure of Protected Health Information on 8/4/2011. All study procedures and investigators are fully HIPAA compliant.
PY - 2013/1
Y1 - 2013/1
N2 - Purpose: To evaluate the effect of subretinal fluid (SRF), imaged with spectral-domain optical coherence tomography (SD-OCT), on visual acuity outcomes in cases of uveitic macular edema (ME), and to analyze the response of SRF and uveitic ME to therapy. Design: Retrospective case series. Methods: One hundred and one eyes of 75 patients with uveitic ME, as imaged by SD-OCT, were identified at a single tertiary-care referral center. The main outcome measures were best-corrected visual acuity, central subfield thickness (CSFT), and rates of macular edema improvement (≥20% reduction in CSFT), and resolution (defined as reduction of CSFT to <315 μm) of ME at 3 and 6 months follow-up. Results: Forty eyes of 29 patients had SRF on SD-OCT at presentation, which was associated with greater macular thickness (mean CSFT 488 μm vs 362 μm, P =.0001) and worse visual acuity than ME without SRF (20/115 vs 20/51, P =.015). However, eyes with SRF responded more favorably to treatment, and at 3 and 6 months of follow-up they achieved greater rates of improvement and resolution of ME than eyes without SRF (77% improved and 50% resolved at 6 months, vs 20% and 13%, respectively; P =.003 and P =.017, respectively) and recovered to a similar level of visual acuity (20/62 vs 20/42 at 6 months, P =.54). Conclusions: SRF in uveitic ME is associated with thicker retinas and worse visual acuity on presentation but responds more favorably to treatment and displays greater rates of edema resolution and visual acuity improvement.
AB - Purpose: To evaluate the effect of subretinal fluid (SRF), imaged with spectral-domain optical coherence tomography (SD-OCT), on visual acuity outcomes in cases of uveitic macular edema (ME), and to analyze the response of SRF and uveitic ME to therapy. Design: Retrospective case series. Methods: One hundred and one eyes of 75 patients with uveitic ME, as imaged by SD-OCT, were identified at a single tertiary-care referral center. The main outcome measures were best-corrected visual acuity, central subfield thickness (CSFT), and rates of macular edema improvement (≥20% reduction in CSFT), and resolution (defined as reduction of CSFT to <315 μm) of ME at 3 and 6 months follow-up. Results: Forty eyes of 29 patients had SRF on SD-OCT at presentation, which was associated with greater macular thickness (mean CSFT 488 μm vs 362 μm, P =.0001) and worse visual acuity than ME without SRF (20/115 vs 20/51, P =.015). However, eyes with SRF responded more favorably to treatment, and at 3 and 6 months of follow-up they achieved greater rates of improvement and resolution of ME than eyes without SRF (77% improved and 50% resolved at 6 months, vs 20% and 13%, respectively; P =.003 and P =.017, respectively) and recovered to a similar level of visual acuity (20/62 vs 20/42 at 6 months, P =.54). Conclusions: SRF in uveitic ME is associated with thicker retinas and worse visual acuity on presentation but responds more favorably to treatment and displays greater rates of edema resolution and visual acuity improvement.
UR - http://www.scopus.com/inward/record.url?scp=84871206302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871206302&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2012.06.028
DO - 10.1016/j.ajo.2012.06.028
M3 - Article
C2 - 23022159
AN - SCOPUS:84871206302
SN - 0002-9394
VL - 155
SP - 143
EP - 149
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 1
ER -